Diluted EPS : $1.20, compared to a loss of $5.89 in the same period in 2024. This improvement reflects lower amortization of acquired intangible assets and the absence of significant one-time charges that were present in the prior year. Business Highlights Revenue Segments The Growth Portfolio, which includes products like Opdivo, Orencia, and Yervoy, showed increased demand and contributed significantly to the company's revenue. However, the Legacy Portfolio faced challenges due to generic competition impacting products such as Revlimid, Sprycel, and Abraxane. Geographical Performance U.S. revenues decreased by 7% due to the impact of generics and changes in the Medicare Part D program. International revenues decreased by 3%, primarily due to foreign exchange impacts. Excluding these impacts, international revenues saw a 2% increase driven by higher demand for the Growth Portfolio and Eliquis.